Cara Therapeutics, Inc. (NASDAQ:CARA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The firm currently has a $14.00 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 11.11% from the stock’s current price.

According to Zacks, “Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. “

CARA has been the topic of a number of other research reports. Stifel Nicolaus reissued a “buy” rating and set a $20.00 price target (down previously from $24.00) on shares of Cara Therapeutics in a report on Friday, June 23rd. Vetr raised Cara Therapeutics from a “buy” rating to a “strong-buy” rating and set a $22.99 price target on the stock in a report on Tuesday, July 4th. Raymond James Financial, Inc. lowered their price target on Cara Therapeutics from $28.00 to $25.00 and set a “market perform” rating on the stock in a report on Thursday, August 3rd. Piper Jaffray Companies set a $27.00 price target on Cara Therapeutics and gave the stock a “buy” rating in a report on Saturday, August 5th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Cara Therapeutics in a report on Friday, August 4th. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $25.50.

Cara Therapeutics (NASDAQ CARA) traded up 2.06% on Wednesday, reaching $12.86. The company’s stock had a trading volume of 1,229,355 shares. The company’s market capitalization is $418.99 million. The firm’s 50 day moving average price is $14.06 and its 200-day moving average price is $16.29. Cara Therapeutics has a 1-year low of $5.27 and a 1-year high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.61) by $0.32. During the same period in the previous year, the business posted ($0.48) EPS. The firm’s revenue for the quarter was down 100.0% compared to the same quarter last year. Equities analysts forecast that Cara Therapeutics will post ($1.78) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Cara Therapeutics, Inc. (CARA) Raised to Buy at Zacks Investment Research” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/30/cara-therapeutics-inc-cara-raised-to-buy-at-zacks-investment-research.html.

In other news, VP Frederique Ph.D. Menzaghi sold 3,000 shares of Cara Therapeutics stock in a transaction that occurred on Friday, July 14th. The shares were sold at an average price of $15.00, for a total transaction of $45,000.00. Following the completion of the sale, the vice president now directly owns 120,000 shares in the company, valued at approximately $1,800,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Dean Slagel sold 250,000 shares of Cara Therapeutics stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $25.87, for a total transaction of $6,467,500.00. The disclosure for this sale can be found here. Insiders sold a total of 278,000 shares of company stock worth $6,888,750 in the last ninety days. 7.50% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of the stock. Legal & General Group Plc increased its stake in Cara Therapeutics by 10.4% in the second quarter. Legal & General Group Plc now owns 7,167 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 678 shares during the last quarter. Fred Alger Management Inc. bought a new stake in Cara Therapeutics during the second quarter worth about $123,000. Quantbot Technologies LP bought a new stake in Cara Therapeutics during the first quarter worth about $124,000. Capital Fund Management S.A. bought a new stake in Cara Therapeutics during the second quarter worth about $171,000. Finally, Rathbone Brothers plc bought a new stake in Cara Therapeutics during the second quarter worth about $185,000. Institutional investors own 61.13% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Get a free copy of the Zacks research report on Cara Therapeutics (CARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.